VO2 Max

A small molecule NNMT inhibitor studied for metabolic enhancement and fat cell reduction.

An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection.

An oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback.

A bifunctional GIPR-antagonist / GLP-1 receptor-agonist peptide in early clinical development for obesity, designed to improve the quality and durability of weight loss and long-term weight maintenance.